Meeting
2022 ASCO Annual Meeting
Preventing adverse events in patients with renal cell carcinoma treated with doublet immunotherapy using fecal microbiota transplantation (FMT): Initial results from perform a phase I study.
Authors
Ricardo Fernandes
London Regional Cancer Program, Western University, London, ON, Canada
Ricardo Fernandes , Seema Nair Parvathy , D. Scott Ernst , Mansour Haeryfar , Jeremy Burton , Michael Silverman , Saman Maleki
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT04163289
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 4553)
DOI
10.1200/JCO.2022.40.16_suppl.4553
Abstract #
4553
Poster Bd #
44
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Association of host immune signatures with response to immunotherapy-based regimens in patients with metastatic renal cell carcinoma (mRCC).
First Author: Eddy Saad
Poster
2023 ASCO Annual Meeting
The study of immune-related adverse events in a community-based centre.
First Author: Sandhya Cautha
First Author: Carolina Alves Costa Silva
Poster
2022 ASCO Annual Meeting
Association between immune-related adverse events and microbiome composition in patients with advanced non–small cell lung cancer treated with immunotherapy.
First Author: Marion Tonneau